Skip to main content
SpringerLink
Log in

Katheterbasierte und operative Therapie bei Mitralklappenvitien

Catheter-based and surgical treatment of mitral valve diseases

  • Schwerpunkt: Neue Aspekte bei Herzklappenerkrankungen
  • Published:
Die Innere Medizin Aims and scope Submit manuscript

Zusammenfassung

Das Spektrum der Mitralklappenerkrankungen ist breit und reicht von jungen Patienten mit rheumatischer Mitralklappenstenose bis hin zu älteren Patienten mit sekundärer Mitralklappeninsuffizienz und zahlreichen Begleiterkrankungen. Ein Verständnis von Ätiologie, anatomischen Merkmalen der Mitralklappenvitien und aktuellen Therapieoptionen ist notwendig, um einen patientenzentrierten Behandlungsplan erstellen zu können. Zentral ist die interdisziplinäre Zusammenarbeit von Zuweisern, interventionellen Kardiologen, Herzchirurgen, Spezialisten aus der Bildgebung und Herzinsuffizienz sowie der Anästhesie.

Abstract

There is a broad spectrum of mitral valve diseases ranging from young patients with rheumatic mitral valve stenosis up to older patients with secondary mitral valve regurgitation and numerous comorbidities. A profound understanding of the etiology, anatomical characteristics of mitral valve diseases and current treatment options is necessary to be able to prepare a patient-centered treatment approach. The interdisciplinary collaboration of referring physicians, interventional cardiologists, cardiac surgeons, heart failure and imaging specialists as well as anesthesiologists is a cornerstone of optimal patient treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Iung B et al (2019) Contemporary Presentation and Management of Valvular Heart Disease: The EURObservational Research Programme Valvular Heart Disease II Survey. Circulation 140(14):1156–1169

    Article  PubMed  Google Scholar 

  2. Zuhlke L et al (2015) Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur Heart J 36(18):1115–122a

    Article  PubMed  Google Scholar 

  3. Vahanian A et al (2022) 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 43(7):561–632

    Article  PubMed  Google Scholar 

  4. Vahanian A et al (2021) 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. https://doi.org/10.1093/eurheartj/ehab395

    Article  PubMed  PubMed Central  Google Scholar 

  5. Wilkins GT et al (1988) Br Heart J 60:299–308

  6. Iung B et al (1996) Circulation 94:2124–2130

  7. Bouleti C et al (2013) Reinterventions after percutaneous mitral commissurotomy during long-term follow-up, up to 20 years: the role of repeat percutaneous mitral commissurotomy. Eur Heart J 34(25):1923–1930

    Article  CAS  PubMed  Google Scholar 

  8. Silbiger, J.J., Advances in Rheumatic Mitral Stenosis: Echocardiographic, Pathophysiologic, and Hemodynamic Considerations. J Am Soc Echocardiogr, 2021. 34(7): p. 709–722 e1.

  9. Guerrero ME et al (2023) 5‑Year Prospective Evaluation of Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Outcomes: MITRAL Trial Final Results. JACC Cardiovasc Interv 16(18):2211–2227

    Article  PubMed  Google Scholar 

  10. Nishimura RA et al (2017) 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 70(2):252–289

    Article  PubMed  Google Scholar 

  11. Russo M et al (2017) The evolution of surgical valves. Cardiovasc Med 20(12):285–292

    Article  Google Scholar 

  12. Carpentier A (1983) Cardiac valve surgery—the “French correction”. J Thorac Cardiovasc Surg 86(3):323–337

    Article  CAS  PubMed  Google Scholar 

  13. Webb JG et al (2020) 1‑Year Outcomes for Transcatheter Repair in Patients With Mitral Regurgitation From the CLASP Study. JACC Cardiovasc Interv 13(20):2344–2357

    Article  PubMed  Google Scholar 

  14. Hausleiter J (2019) Early procedural outcomes from subjects treated with next-generation MitraClip (NTR/XTR) system: initial observations from the Global EXPAND study, in EuroPCR. Paris, France

    Google Scholar 

  15. Stone GW et al (2018) Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 379(24):2307–2318

    Article  PubMed  Google Scholar 

  16. Lim DS et al (2022) Randomized Comparison of Transcatheter Edge-to-Edge Repair for Degenerative Mitral Regurgitation in Prohibitive Surgical Risk Patients. JACC Cardiovasc Interv 15(24):2523–2536

    Article  PubMed  Google Scholar 

  17. Muller DWM et al (2017) Transcatheter Mitral Valve Replacement for Patients With Symptomatic Mitral Regurgitation: A Global Feasibility Trial. J Am Coll Cardiol 69(4):381–391

    Article  PubMed  Google Scholar 

  18. Baumgartner H et al (2017) 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 38(36):2739–2791

    Article  PubMed  Google Scholar 

  19. Asgar, A.W., M.J. Mack, and G.W. Stone, Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol, 2015. 65(12): p. 1231–1248.

  20. McDonagh TA et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599–3726

    Article  CAS  PubMed  Google Scholar 

  21. Kang DH et al (2019) Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation. Circulation 139(11):1354–1365

    Article  CAS  PubMed  Google Scholar 

  22. Obadia JF et al (2018) Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med 379(24):2297–2306

    Article  PubMed  Google Scholar 

  23. Mack MJ et al (2021) 3‑Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure. J Am Coll Cardiol 77(8):1029–1040

    Article  PubMed  Google Scholar 

  24. Higuchi S et al (2021) Impact of Residual Mitral Regurgitation on Survival After Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation. JACC Cardiovasc Interv 14(11):1243–1253

    Article  PubMed  Google Scholar 

  25. Kar S et al (2021) Relationship Between Residual Mitral Regurgitation and Clinical and Quality-of-Life Outcomes After Transcatheter and Medical Treatments in Heart Failure: COAPT Trial. Circulation 144(6):426–437

    Article  PubMed  Google Scholar 

  26. Keller K et al (2021) Centre procedural volume and adverse in-hospital outcomes in patients undergoing percutaneous transvenous edge-to-edge mitral valve repair using MitraClip(R) in. Eur J Heart Fail, Germany

    Book  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Kardiologie und Angiologie, Universitäts-Herzzentrum Freiburg/Bad Krozingen, Universitätsklinikum Freiburg, Südring 15, 79189, Bad Krozingen, Deutschland

    Mirjam G. Wild, Dirk Westermann &  Christian Besler

  2. Klinik für Herz- und Gefäßchirurgie, Universitäts-Herzzentrum Freiburg/Bad Krozingen, Universitätsklinikum Freiburg, Freiburg, Deutschland

    Wolfgang Bothe & Martin Czerny

Authors
  1. Mirjam G. Wild
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang Bothe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dirk Westermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martin Czerny
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christian Besler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Besler.

Ethics declarations

Interessenkonflikt

M.G. Wild hat Vortragshonoraria und Reisekostenübernahme von Edwards Lifesciences sowie Vortragshonoraria von Abbott Vascular erhalten. C. Besler hat Vortragshonoraria und Reisekostenübernahme von Edwards Lifesciences sowie Vortragshonoraria von Abbott Vascular erhalten. D. Westermann hat Vortragshonoraria und Reisekostenübernahme von Abiomed, Abbott, AstraZeneca, Bayer, Böhringer Ingelheim, Daiichi Sankyo, Edwards Lifesciences, Medtronic und Novartis erhalten. M. Czerny ist Berater für Terumo Aortic und Medtronic, hat Vortragshonoraria von Edwards Lifesciences erhalten und ist Aktienhalter von TEVAR Ltd. und Ascense Medical. W. Bothe gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

Gerd Hasenfuß, Göttingen

Hinweis des Verlags

Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wild, M.G., Bothe, W., Westermann, D. et al. Katheterbasierte und operative Therapie bei Mitralklappenvitien. Innere Medizin 65, 439–446 (2024). https://doi.org/10.1007/s00108-024-01703-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-024-01703-5

Schlüsselwörter

Keywords

Search

Navigation